Fluprednidene is a corticosteroid.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Fluprednidene. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluprednidene. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluprednidene. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluprednidene. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluprednidene. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluprednidene. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluprednidene. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednidene. |
| Pegaspargase | The serum concentration of Fluprednidene can be increased when it is combined with Pegaspargase. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednidene. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednidene. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednidene. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednidene. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednidene. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednidene. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednidene. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednidene. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednidene. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednidene. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednidene. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednidene. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednidene. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluprednidene. |
| Cladribine | Fluprednidene may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluprednidene. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluprednidene. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluprednidene. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluprednidene. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluprednidene. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluprednidene. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluprednidene. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluprednidene. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluprednidene. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluprednidene. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluprednidene. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluprednidene. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluprednidene. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluprednidene. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluprednidene. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluprednidene. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Fluprednidene. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluprednidene. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluprednidene. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluprednidene. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluprednidene. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluprednidene. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Fluprednidene. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluprednidene. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fluprednidene. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluprednidene. |
| Tretinoin | The metabolism of Tretinoin can be increased when combined with Fluprednidene. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluprednidene. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Fluprednidene. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Fluprednidene. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Fluprednidene. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluprednidene. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluprednidene. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Fluprednidene. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fluprednidene. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednidene. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Fluprednidene. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fluprednidene. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluprednidene. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Fluprednidene. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Fluprednidene. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluprednidene. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Fluprednidene. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Fluprednidene. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluprednidene. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Fluprednidene. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Fluprednidene. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluprednidene. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Fluprednidene. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Fluprednidene. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Fluprednidene. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Fluprednidene. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Fluprednidene. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluprednidene. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Fluprednidene. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Fluprednidene. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Fluprednidene. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Fluprednidene. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluprednidene. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Interferon alfa is combined with Fluprednidene. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Fluprednidene. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Fluprednidene. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Fluprednidene. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Fluprednidene. |
| Abetimus | The risk or severity of adverse effects can be increased when Abetimus is combined with Fluprednidene. |
| Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Fluprednidene. |
| Bendamustine | The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluprednidene. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluprednidene. |
| Wortmannin | The risk or severity of adverse effects can be increased when Wortmannin is combined with Fluprednidene. |
| Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Fluprednidene. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Fluprednidene. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluprednidene. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Carfilzomib is combined with Fluprednidene. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Fluprednidene. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Fluprednidene. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Fluprednidene is combined with Vedolizumab. |